Programs & products

Innate pharma presents encouraging data on its immunomodulatory product candidate IPH 1101 with final results from phase I clinical trial in solid tumours (Trial D004-101).

Innate Pharma strengthens its platform in the pharmacology of Toll-like-receptors (TLR) with assets licensed from US-based global pharmaceutical company Schering-Plough Corporation and advanced R&D...

Innate pharma presents encouraging data on IPH 1101 at the American society of clinical oncology's 2006 annual meeting and moves its drug candidate into phase II kidney cancer clinical trial.

Innate Pharma and Novo Nordisk announce strategic partnership to research and develop drugs targeting natural killer cells.

Innate Pharma SA announced that its partnership with Novo Nordisk A/S is being refocused to the inflammatory field.

Innate Pharma SA announces today the entry into regulatory pre-clinical development of IPH 2301, a novel monoclonal antibody targeting NK (Natural Killer) and T cells. It is the first antibody from...

Innate Pharma SA today announces results for its Phase IIa study with IPH 1101, an agonist of gamma delta T cells, as a second line monotherapy in metastatic renal cell carcinoma. In connection with...

Innate Pharma SA announces today that IPH 1101 in combination with rituximab was authorized to enter the second part of the Phase I/II trial in follicular non-Hodgkin's lymphoma.

Innate Pharma SA announces that it has acquired the worldwide exclusive development and commercial rights to IPH2101 from Novo Nordisk A/S in the context of a swap of products.

Innate Pharma SA announces that the preclinical rationale of the gamma-delta T cell immunotherapy in type-C viral hepatitis was presented today at the AASLD (American Association for the Study of...